Healthcare
Our healthcare equity research is broad in scope and in-depth in content and analysis. In addition to company-specific research, our team publishes sector overviews that seek to identify emerging trends and ways investors can benefit from these changes as well as inherent risks. Our Healthcare research includes healthcare services, healthcare information technology (IT), medical devices, biotechnology, biopharmaceuticals, and specialty pharmaceuticals.
Joel Sendek
Title:Head of our Life Sciences Equity Research
Joel Sendek is a Managing Director and Head of our Life Sciences Equity Research team. Prior to joining Oppenheimer, Joel held CFO positions at four different biotech companies. Prior to that Joel was a senior analyst covering biotechnology at Lazard and subsequently Stifel where he also served as head of the healthcare equity research group. Joel has covered over 100 companies during the course of his sell-side career ranging from profitable large-caps to microcap biotech companies. Joel has been recognized by The Wall Street Journal as an All-Star Analyst with a number one ranking for stock picking. Earlier in his career he worked in business development at Progenics Pharmaceuticals and as an investment banker at Goldman Sachs. He has a biochemistry degree from Rice University.
Trevor Allred
Title:Biotechnology
Trevor Allred is a Senior Analyst covering Biotechnology. Trevor has been with Oppenheimer since 2019. Prior to joining Oppenheimer, Trevor spent over five years working as a Clinical Laboratory Scientist before pursuing his MBA. Trevor holds a Bachelor of Science degree in Medicinal Chemistry and Molecular Pharmacology from Purdue University, and a Master in Business Administration from Indiana University’s Kelley School of Business.
Andreas Argyrides
Title:Biotechnology
Andreas Argyrides is an Executive Director and Senior Analyst covering Biotechnology. Prior to joining Oppenheimer, Andreas was Vice President and Senior Analyst covering Biotechnology at Wedbush. Prior to Wedbush, Andreas spent a decade in various roles across the healthcare industry including as healthcare sector specialist and research analyst at a long/short biotech focused hedge fund. Andreas received his BA in History and Economics with honors from New York University.
Matt Biegler
Title:Emerging Biotechnology
Matt Biegler is a Senior Analyst covering Emerging Biotechnology. Prior to joining Oppenheimer, Matt worked with Mark Breidenbach covering Biotechnology. Prior to his Wall Street career, Matt spent over five years in the healthcare industry, most recently as a Consultant at Parexel International, a Contract Research Organization. His areas of expertise include clinical trial design and strategy. Matt holds a Bachelor’s degree in Biochemistry and Molecular Biology from Boston University, and a Master’s in Biotechnology from the Columbia University Graduate School of Arts and Sciences.
François Brisebois
Title:Biotechnology
François Brisebois is a Managing Director and Senior Analyst covering Biotechnology. Prior to joining Oppenheimer, he was a Senior Research Analyst at Craig-Hallum Capital covering Biotechnology and Biopharmaceuticals. He previously worked at Laidlaw Capital Markets as a Senior Analyst covering Biotechnology and Specialty Pharmaceuticals and started his Wall Street career at healthcare specialty firm Summer Street Research Partners. Frank holds a Bachelor’s degree in Molecular Biology from Colgate University and a Master of Science in Pharmaceutical Sciences from University of Montreal.
Leland Gershell
Title:BioPharmaceuticals
Leland Gershell is a Managing Director and Senior Analyst covering BioPharmaceuticals. Prior to joining Oppenheimer, Leland was Chief Financial Officer of Capricor Therapeutics and Tonix Pharmaceuticals. Leland also has both sell-side and buy-side experience and began his career on Cowen's biotechnology research team, where he provided sole coverage focused in the small and mid-cap segment. Leland has also authored numerous editorial and review articles and is an inventor on patents for Merck's Zolinza®. He earned his MD and Ph.D. in Organic Chemistry from Columbia University and his BA magna cum laude in Chemistry and Asian Studies from Dartmouth College.
Jeff Jones
Title:Biotechnology
Jeff Jones is a Managing Director and Senior Analyst covering Biotechnology. Prior to joining Oppenheimer, Jeff founded and ran One Health Advisors, LLC which provided strategic advisory services for the human and animal biopharma sector. Prior to founding One Health, Jeff had served in numerous roles with biotechnology companies, including Vice President of Business Development at Aratana Therapeutics and COO at Pharmathene. Jeff received an B.A. in Biology from University of Virginia and a Ph.D. in Cell & Molecular Biology from Baylor College of Medicine. He has also completed an M.B.A. at Cornell University, Johnson Graduate School of Management.
Jay Olson, CFA
Title:Biotechnology
Jay Olson is Managing Director and Senior Analyst covering Biotechnology. Prior to joining Oppenheimer, Jay covered SMID-cap names and worked on the Large Cap Pharmaceuticals team at Goldman Sachs for 4 years after 4 years on the #1 II-ranked Large Cap Pharmaceuticals team at Sanford Bernstein. Prior to Wall Street, Jay spent 18 years in the pharmaceutical industry, working mostly for Pfizer in finance, marketing and business development. Jay received an MBA in Finance and an MS in Chemical Engineering both from MIT, and a BS in Chemical Engineering from Tufts University. He also holds the CFA designation.
Suraj Kalia, CFA
Title:Medical Technology and Devices
Suraj Kalia is Managing Director and Senior Analyst covering Medical Technology and Devices. Previously, Suraj was Managing Director at Northland Securities. He has over 15 years of sell-side research experience and in 2018 was ranked #1 Healthcare Equipment & Supplies Analyst by Thomson Reuters. He has held senior equity research analyst positions at Rodman & Renshaw, Sanders Morris, Harris and Piper Jaffray. He also worked at Entegris Inc. in Business Development and at the University of St. Thomas in Minneapolis as an Adjunct Professor of Finance. Suraj holds a Bachelor’s degree in Technology Chemical Engineering from Indian Institute of Technology and a Master of Engineering in Chemical Engineering from Stevens Institute of Technology. He holds an M.B.A. from University of St. Thomas and the CFA certification.
Steven M. Lichtman
Title:Medical Devices
Steven Lichtman is Managing Director and Senior Analyst for Medical Devices. Steve has been on the sell side following the Medical Devices sector for over 20 years, including 18 as a senior analyst. Prior to joining Oppenheimer to cover Medical Devices, he held that role at JMP Securities and Banc of America Securities. Prior to Banc of America, Steve was the Senior Associate on leading Medical Devices teams at Credit Suisse First Boston and Schroder & Company, Inc. Steve received a B.A. from Duke University in Economics and Public Policy Studies and a M.B.A. from New York University's Stern School of Business.
Michael Wiederhorn
Title:Healthcare Providers
Michael Wiederhorn is Managing Director and Senior Analyst covering Healthcare Providers and Services. His coverage focuses on managed care, hospitals, nursing homes, home health, hospice, emergency services, and related healthcare services. He has over fifteen years of experience in healthcare consulting and research and in 2013, he was honored as a top ranked Earnings Estimator in Health Care Providers & Services 2013 by Financial Times/Starmine. In addition, in 2009 and 2010, Michael was ranked the #1 brokerage analyst for Medical Care by Forbes Magazine. Prior to entering equity research, Michael was a management consultant at Ernst and Young, serving the healthcare industry. He has a Masters in Health Policy and Management from Harvard University and BA in American History from the University of Pennsylvania.